EP Wealth Advisors LLC Invests $110,000 in Emergent BioSolutions Inc. (NYSE:EBS)

EP Wealth Advisors LLC purchased a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,459 shares of the biopharmaceutical company’s stock, valued at approximately $110,000.

Several other large investors also recently made changes to their positions in EBS. Invesco Ltd. boosted its stake in shares of Emergent BioSolutions by 70.9% during the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after acquiring an additional 638,995 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after acquiring an additional 444,790 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Emergent BioSolutions by 23.4% during the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock worth $20,437,000 after acquiring an additional 404,667 shares in the last quarter. Trexquant Investment LP boosted its stake in shares of Emergent BioSolutions by 59.3% during the 4th quarter. Trexquant Investment LP now owns 701,517 shares of the biopharmaceutical company’s stock worth $6,707,000 after acquiring an additional 261,099 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Emergent BioSolutions during the 4th quarter worth about $1,831,000. Institutional investors own 78.40% of the company’s stock.

Insider Buying and Selling at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now directly owns 101,100 shares of the company’s stock, valued at approximately $589,413. This represents a 25.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $5.51 on Friday. The business has a 50 day moving average price of $5.13 and a 200 day moving average price of $7.82. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company has a market cap of $299.40 million, a price-to-earnings ratio of -1.34 and a beta of 2.09. Emergent BioSolutions Inc. has a twelve month low of $4.02 and a twelve month high of $15.10.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.49 by $0.22. The firm had revenue of $222.20 million during the quarter, compared to analysts’ expectations of $218.50 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. Research analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Emergent BioSolutions declared that its Board of Directors has initiated a share buyback program on Monday, March 31st that authorizes the company to repurchase $50.00 million in shares. This repurchase authorization authorizes the biopharmaceutical company to purchase up to 19% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on EBS shares. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, April 1st. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.